De Sanctis V, Vullo C, Katz M, Wonke B, Nannetti C, Bagni B
Department of Paediatrics, Unità Sanitaria Locale 31, Arcispedale S. Anna, Ferrara, Italy.
Fertil Steril. 1988 Dec;50(6):969-75. doi: 10.1016/s0015-0282(16)60382-5.
In an attempt to induce or to augment pubertal development and to achieve spermatogenesis, 10 gonadotropin-deficient thalassemic patients 15 to 23 years of age (mean 18.9 years) were treated with exogenous gonadotropins for 1 to 4 years (mean 2.1 years). Seven patients produced sperm during human chorionic gonadotropin (hCG) treatment given for 6 to 14 months. However, full spermatogenesis was achieved only when human menopausal gonadotropin was added to hCG regimen. In one patient, despite cessation of gonadotropin treatment, sexual potency, libido, and spermatogenetic capacity were maintained during the past 2 1/2 years. Our study indicates that it is possible to induce or to restore spermatogenesis in the majority of thalassemic patients and that gonadotrope cells may not be irreversibly damaged by iron deposition.
为了诱导或增强青春期发育并实现精子发生,对10名年龄在15至23岁(平均18.9岁)的促性腺激素缺乏型地中海贫血患者给予外源性促性腺激素治疗1至4年(平均2.1年)。7名患者在接受人绒毛膜促性腺激素(hCG)治疗6至14个月期间产生了精子。然而,只有当在hCG治疗方案中加入人绝经期促性腺激素时才实现了完全精子发生。在一名患者中,尽管停止了促性腺激素治疗,但在过去的2年半中其性功能、性欲和精子发生能力得以维持。我们的研究表明,在大多数地中海贫血患者中诱导或恢复精子发生是可能的,并且促性腺细胞可能不会因铁沉积而受到不可逆转的损害。